N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC, a specialist pharmaceutical company, announced its final results for 2023, highlighting advancements in their Nuvec® delivery system for cancer treatments and vaccines. The company reported a comprehensive loss of £1,276,778, but expressed optimism due to achievements like patents granted for Nuvec® across multiple regions, a controlling stake acquisition in Nanogenics Limited, and anticipated collaborations with a US R&D leader. Despite a cash decrease to £1.0m, the CEO remains positive about the future.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
